PreprintArticleVersion 1This version is not peer-reviewed
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratio: Side by Side with Molecular Mutations in Patients with Non-small Cell Lung Cancer. The INOLUNG Study
Version 1
: Received: 3 July 2024 / Approved: 4 July 2024 / Online: 6 July 2024 (03:29:58 CEST)
How to cite:
Budin, C. E.; Cocuz, I. G.; Enache, L. S.; Rența, I. A.; Cazacu, C.; Pătrîntașu, D. E.; Olteanu, M.; Râjnoveanu, R.-M.; Ianoși, E. S.; Râjnoveanu, A.; Cotoi, O. S. Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratio: Side by Side with Molecular Mutations in Patients with Non-small Cell Lung Cancer. The INOLUNG Study. Preprints2024, 2024070487. https://doi.org/10.20944/preprints202407.0487.v1
Budin, C. E.; Cocuz, I. G.; Enache, L. S.; Rența, I. A.; Cazacu, C.; Pătrîntașu, D. E.; Olteanu, M.; Râjnoveanu, R.-M.; Ianoși, E. S.; Râjnoveanu, A.; Cotoi, O. S. Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratio: Side by Side with Molecular Mutations in Patients with Non-small Cell Lung Cancer. The INOLUNG Study. Preprints 2024, 2024070487. https://doi.org/10.20944/preprints202407.0487.v1
Budin, C. E.; Cocuz, I. G.; Enache, L. S.; Rența, I. A.; Cazacu, C.; Pătrîntașu, D. E.; Olteanu, M.; Râjnoveanu, R.-M.; Ianoși, E. S.; Râjnoveanu, A.; Cotoi, O. S. Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratio: Side by Side with Molecular Mutations in Patients with Non-small Cell Lung Cancer. The INOLUNG Study. Preprints2024, 2024070487. https://doi.org/10.20944/preprints202407.0487.v1
APA Style
Budin, C. E., Cocuz, I. G., Enache, L. S., Rența, I. A., Cazacu, C., Pătrîntașu, D. E., Olteanu, M., Râjnoveanu, R. M., Ianoși, E. S., Râjnoveanu, A., & Cotoi, O. S. (2024). Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratio: Side by Side with Molecular Mutations in Patients with Non-small Cell Lung Cancer. The INOLUNG Study. Preprints. https://doi.org/10.20944/preprints202407.0487.v1
Chicago/Turabian Style
Budin, C. E., Armand Râjnoveanu and Ovidiu Simion Cotoi. 2024 "Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratio: Side by Side with Molecular Mutations in Patients with Non-small Cell Lung Cancer. The INOLUNG Study" Preprints. https://doi.org/10.20944/preprints202407.0487.v1
Abstract
Background and objective: Analysis of inflammatory biomarkers, along with the neutrophil/lymphocyte ratio (NLR) or platelets/lymphocyte ratio (PLR), supports the connection between inflammation and carcinogenesis. Methods: We conducted a retrospective observational study at the Clinical County Hospital Mureș, including patients with lung cancer. The parameters analyzed included: histopathological type (NSCLC - squamous cell carcinoma or adenocarcinoma; SCLC), molecular mutations (EGFR, ALK, PD-L1), parameters from the complete blood count, inflammatory parameters and associated comorbidities. Results: 380 patients were included: 115 patients in the cancer group and 265 patients in the control group. Among patients in the lung cancer group, 88 were diagnosed with NSCLC (44 adenocarcinomas, 44 squamous cell carcinomas) and 27 with SCLC. Both NLR and PLR were significantly higher in cancer patients than in the control group (5,30 versus 2,60, p<0,001; 217 versus 136, p< 0.001, respectively). NLR and PLR differs between men and women (p = 0.005, respectively p=0.056). C-reactive protein was not correlated with either NLR (p-value: 0.0669) or PLR (p-value: 0.6733) in lung cancer patients. Conclusion: The NLR and PLR values may serve as new predictive biomarkers for the diagnostic of disease in patients with lung cancer, especially those with NSCLC.
Keywords
Neutrophil to lymphocyte ratio (NLR); Platelets to lymphocite ratio (PLR); Non Small Cell Lung Cancer (NSCLC); molecular mutations; EGFR
Subject
Medicine and Pharmacology, Pulmonary and Respiratory Medicine
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
